South San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, ShouTi is raising $25,999,992.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Raymond Stevens played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About ShouTi
ShouTi creates life-changing medicines for patients using advanced computational and structure-based technology. Our platform combines the latest advancements in computational chemistry, visualization of molecular interactions, and data integration to design orally available, superior medicines that overcome current limitations in biologic and peptide drugs. We are advancing our clinical-stage pipeline of differentiated, efficacious and safe treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic and pulmonary conditions. At ShouTi, our teams deep experience with complex biological targets and mechanisms, structure-based drug design, and global drug discovery and development enables our bold vision: to design and develop world-class medicines with tremendous patient impact and broad commercial opportunity.

To learn more about ShouTi, visit http://shoutipharma.com/

Contact:
Raymond Stevens, Chief Executive Officer
650-339-6828
https://www.linkedin.com/in/raymond-stevens-737a34129/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved